RAPP — Rapport Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.16bn
- $648.48m
- 40
- 33
- 85
- 52
Annual cashflow statement for Rapport Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -10.7 | -34.8 | -78.3 |
| Depreciation | |||
| Non-Cash Items | 5.91 | 4.84 | 15.1 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 1.49 | 2.65 | -2.42 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -3.24 | -27.2 | -64.8 |
| Capital Expenditures | -0.284 | -1.64 | -2.4 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -5 | -77.2 | -168 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -5.28 | -78.9 | -170 |
| Financing Cash Flow Items | 31.7 | 59.8 | 0 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 39.7 | 145 | 222 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 31.2 | 39.1 | -13.3 |